To generalize these findings across different tumor types and immunotherapeutic strategies, we then calculated the proportion of responders and non-responders in high- and low-PSMB9 subgroups within melanoma patients receiving adoptive cell transfer (ACT) therapy (GSE100797) [33] and STAD patients treated with anti-PD-1 therapy (PRJEB25780) [25] (Figure 6F,G). Here, PDCD1 is linked to neoplasm.